Single-cell genomics-based immune and disease monitoring in blood malignancies.

Q4 Health Professions Clinical hematology international Pub Date : 2024-06-14 eCollection Date: 2024-01-01 DOI:10.46989/001c.117961
Anja C Rathgeber, Leif S Ludwig, Livius Penter
{"title":"Single-cell genomics-based immune and disease monitoring in blood malignancies.","authors":"Anja C Rathgeber, Leif S Ludwig, Livius Penter","doi":"10.46989/001c.117961","DOIUrl":null,"url":null,"abstract":"<p><p>Achieving long-term disease control using therapeutic immunomodulation is a long-standing concept with a strong tradition in blood malignancies. Besides allogeneic hematopoietic stem cell transplantation that continues to provide potentially curative treatment for otherwise challenging diagnoses, recent years have seen impressive progress in immunotherapies for leukemias and lymphomas with immune checkpoint blockade, bispecific monoclonal antibodies, and CAR T cell therapies. Despite their success, non-response, relapse, and immune toxicities remain frequent, thus prioritizing the elucidation of the underlying mechanisms and identifying predictive biomarkers. The increasing availability of single-cell genomic tools now provides a system's immunology view to resolve the molecular and cellular mechanisms of immunotherapies at unprecedented resolution. Here, we review recent studies that leverage these technological advancements for tracking immune responses, the emergence of immune resistance, and toxicities. As single-cell immune monitoring tools evolve and become more accessible, we expect their wide adoption for routine clinical applications to catalyze more precise therapeutic steering of personal immune responses.</p>","PeriodicalId":93942,"journal":{"name":"Clinical hematology international","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11180218/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical hematology international","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.46989/001c.117961","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"Health Professions","Score":null,"Total":0}
引用次数: 0

Abstract

Achieving long-term disease control using therapeutic immunomodulation is a long-standing concept with a strong tradition in blood malignancies. Besides allogeneic hematopoietic stem cell transplantation that continues to provide potentially curative treatment for otherwise challenging diagnoses, recent years have seen impressive progress in immunotherapies for leukemias and lymphomas with immune checkpoint blockade, bispecific monoclonal antibodies, and CAR T cell therapies. Despite their success, non-response, relapse, and immune toxicities remain frequent, thus prioritizing the elucidation of the underlying mechanisms and identifying predictive biomarkers. The increasing availability of single-cell genomic tools now provides a system's immunology view to resolve the molecular and cellular mechanisms of immunotherapies at unprecedented resolution. Here, we review recent studies that leverage these technological advancements for tracking immune responses, the emergence of immune resistance, and toxicities. As single-cell immune monitoring tools evolve and become more accessible, we expect their wide adoption for routine clinical applications to catalyze more precise therapeutic steering of personal immune responses.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
基于单细胞基因组学的血液恶性肿瘤免疫和疾病监测。
利用治疗性免疫调节实现长期疾病控制是血液恶性肿瘤领域一个历史悠久的概念,并具有深厚的传统。除了异基因造血干细胞移植继续为其他具有挑战性的诊断提供潜在的治愈性治疗外,近年来,免疫检查点阻断、双特异性单克隆抗体和 CAR T 细胞疗法在白血病和淋巴瘤的免疫治疗方面也取得了令人瞩目的进展。尽管这些疗法取得了成功,但无应答、复发和免疫毒性仍很常见,因此,阐明潜在机制和确定预测性生物标志物成为当务之急。现在,单细胞基因组工具的可用性越来越高,可提供系统免疫学视角,以前所未有的分辨率解析免疫疗法的分子和细胞机制。在此,我们回顾了利用这些技术进步跟踪免疫反应、免疫耐受的出现和毒性的最新研究。随着单细胞免疫监测工具的发展和普及,我们希望它们能广泛应用于常规临床,以促进对个人免疫反应进行更精确的治疗指导。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
1.30
自引率
0.00%
发文量
0
审稿时长
20 weeks
期刊最新文献
Management of multiple myeloma presenting as malignant spinal cord compression during pregnancy: a case report. Overview of approved CAR-T products and utility in clinical practice. Multidisciplinary Management of Morbidities Associated with Chronic Graft-Versus-Host Disease. Pulmonary GvHD: is it time to change the NIH diagnostic criteria? Delivering an impactful presentation: a practical guide.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1